TrialBlood2019

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Andres Forero-Torres et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.